ArticleJournal of neuro-oncology2026
Glioma region-specific metabolites associated with patient seizures.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSeizures are often the first and only clinical symptom of glioma presence, especially in low-grade tumors. Anti-epilepsy drugs have shown mixed success due to tumor-induced biochemical changes that uniquely alter brain tissue functionality and activity. Recently, it was shown that glioma metabolism is differentially dysregulated between core (contrast enhancing) and edge (T2/FLAIR hyperintense) tissue. To provide insight into the biochemical alterations underlying seizures, this study hypothesized that glioma region-specific metabolites could be associated with seizure occurrence.
methodsLog-transformed metabolite signal intensities were obtained by 2D liquid chromatography mass spectrometry/mass spectrometry of patient core and edge glioma samples (n = 39 patients). To identify metabolites associated with seizure occurrence, metabolites were used as features for classification of seizure via machine learning, including forward feature selection and rigorous model validation using repeated cross-validation and a test (holdout) set.
resultsPre-op seizure occurrence could be accurately classified with five core metabolites (AUROC
conclusionTumor region-specific metabolites in glioma patients were associated with seizure occurrence, identifying metabolomic dysregulation potentially reflecting biochemical alterations. This study represents a first step towards identifying metabolites linked to seizure occurrence, with the ultimate goal of improving glioma patient outcomes.
Indexed as
Identifiers
42288706What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.